First author Cullen Taniguchi, M.D., Ph.D., passed away suddenly before the final publication of this study. A talented physician-scientist motivated by the impact of cancer on his own family, Taniguchi was committed to improving treatment options and outcomes for patients with gastrointestinal cancers as well as mentoring aspiring physicians and scientists.
“Dr. Taniguchi was a pioneer, committed to not accepting the low...
A team of researchers at The University of Texas MD Anderson Cancer Center has developed a new method for using extracellular vesicles to...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Researchers at The University of Texas MD Anderson Cancer Center have discovered that certain nano-based cancer therapies may be less effective in younger patients, highlighting the need for further investigation into the impact of aging on the body’s ability to respond to treatment.
The researchers found age-related differences are due to how effectively the liver filters the bloodstream. Younger livers are more efficient at this...
A new study by researchers at The University of Texas MD Anderson Cancer Center highlights novel insights into the evolution of multiple myeloma...
A new study led by researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Medicine, provides a deeper...
ABSTRACTS: CT016, CT018
Researchers from The University of Texas MD Anderson Cancer Center presented promising findings...
ABSTRACT: CT006
The first-in-class YAP/TEAD inhibitor VT3989 was well tolerated with durable antitumor responses in patients with advanced...
A study from researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Cell Biology, details a previously...
Three researchers at The University of Texas MD Anderson Cancer Center have been named fellows of the American Association for the Advancement...
A team of researchers led by The University of Texas MD Anderson Cancer Center has developed a novel delivery system for messenger RNA (mRNA...
Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved...